Serologic Prevalence of Ebola Virus in Equatorial Africa
Imke Steffen
1, Kai Lu, Lauren K. Yamamoto, Nicole A. Hoff, Prime Mulembakani, Emile O. Wemakoy, Jean-Jacques Muyembe-Tamfum, Nicaise Ndembi, Catherine A. Brennan, John Hackett, Susan L. Stramer, William M. Switzer, Sentob Saragosti, Guy O. Mbensa, Syria Laperche, Anne W. Rimoin, and Graham Simmons
Author affiliations: Vitalant Research Institute, San Francisco, California, USA (I. Steffen, K. Lu, L.K. Yamamoto, G. Simmons); University of California, San Francisco (I. Steffen, K. Lu, G. Simmons); University of California, Los Angeles, California, USA (N.A. Hoff, A.W. Rimoin); University of Kinshasa, Kinshasa, Democratic Republic of the Congo (P. Mulembakani, E.O. Wemakoy); Institut National de Recherche Biomedicale, Kinshasa (J.-J. Muyembe-Tamfum); Institute of Human Virology, Abuja, Nigeria (N. Ndembi); Abbott Diagnostics, Abbott Park, Illinois, USA (C.A. Brennan, J. Hackett Jr.); American Red Cross Scientific Support Office, Gaithersburg, Maryland, USA (S.L. Stramer); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.M. Switzer); Institut National de la Santé et de la Recherche Médicale Unité 941, Paris, France (S. Saragosti); Centre National de Transfusion Sanguine, Kinshasa (G.O. Mbensa); Institut National de la Transfusion Sanguine, Paris (S. Laperche)
Main Article
Figure 2
Figure 2. High-throughput screening data for neutralizing antibodies against EBOV and MACV glycoprotein pseudotypes in serum samples in study of serologic prevalence of Ebola virus in equatorial Africa. A) Uganda; B) Cameroon; C) Ghana; D) southern Cameroon; E) Republic of the Congo; F) Kinshasa, Democratic Republic of the Congo; G) Kasaï Oriental Province, Democratic Republic of the Congo. Serum samples were tested at a 1:50 dilution against the different pseudotypes. Samples that reduced pseudotype infectivity by >50% compared with a negative serum control were considered positive and confirmed by titration. Error bars indicate 95% CIs. EBOV, Ebola virus; MACV, Machupo virus.
Main Article
Page created: April 17, 2019
Page updated: April 17, 2019
Page reviewed: April 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.